Headquartered in La Jolla, CA·Fiscal year ends December·NASDAQ: EQ·equilliumbio.com
About Equillium
Equillium, Inc. (Nasdaq: EQ) is a clinical-stage biotechnology company developing therapies for serious autoimmune and inflammatory disorders. Its lead and current focus is EQ504, an investigational, potent and selective small-molecule aryl hydrocarbon receptor (AhR) modulator. EQ504 has a multi-modal immunoregulatory mechanism of action without broad immune suppression and is designed to be complementary to other inflammation and immunology agents. AhR is critical to barrier organ tissue physiology and immunology: it maintains barrier function, promotes tissue repair and regeneration, and regulates resident immune cells toward anti-inflammatory responses. For ulcerative colitis, EQ504 is formulated as an oral, colon-targeted delayed-release drug product. The company is also evaluating inhaled formulations for inflammatory lung diseases. EQ504 entered a first-in-human Phase 1 trial in healthy volunteers in October 2026, with proof-of-mechanism data expected in Q2 2027 and a planned ulcerative colitis proof-of-concept study in the second half of 2027. The company generates no product revenue and funds operations through equity financing, including a tranched private placement agreement announced in August 2025 whose second tranche closed in October 2026. Updated
These are four stocks for aggressive investors looking to get share count leverage on companies that have sizable upside potential. They are not penny stocks with absolutely no track record or liquidity,…
Equillium, Inc. (Nasdaq: EQ) is a clinical-stage biotechnology company developing therapies for serious autoimmune and inflammatory disorders. Its lead and current focus is EQ504, an investigational, potent and selective small-molecule aryl hydrocarbon receptor (AhR) modulator.
What is the EQ stock price target?
The Wall Street consensus 12-month price target for EQ is $8.56.